Clinical Trials Logo

Clinical Trial Summary

This is a single-center, randomized, double-blind, placebo-controlled trial. A total of 100 patients, 50 per treatment arm, undergoing minimally invasive thoracic surgery will be randomized 1:1 across 2 treatment arms: Ofiramev® (acetaminophen) injection 1,000 mg (100 mL) plus patient-controlled analgesia (PCA) and 100 mL placebo plus PCA.


Clinical Trial Description

This is a single-center, randomized, double-blind, placebo-controlled trial. A total of 100 patients, 50 patient per treatment arm, undergoing minimally invasive thoracic surgery will be randomized 1:1 across 2 treatment arms: Ofiramev® (acetaminophen) injection 1,000 mg (100 mL) plus patient-controlled analgesia (PCA) and 100 mL placebo plus PCA. All patients will be enrolled from a single site.50 patient will be enrolled in each arm (placebo/ acetamophin). Each subject will be administered a single dose of study drug or placebo infused over 15-minutes, four times, six hours apart. The duration of subject participation will be ten weeks. Total duration of the study is expected to be 52 weeks. The primary endpoints of the study will be the amount of postoperative narcotic used, patient assessment of pain as measured by a validated pain survey, and length of stay in the hospital.

For postoperative pain assessment, the Numeric Rating Scale (NRS) will be used (NRS: 0-10; 0: no pain, 10: worst pain imaginable). Pain will be evaluated at 2-hour intervals in the post-anesthesia care unit followed by 4-hour intervals once the patient is transferred to the floor. Nurses who are blinded to the analgesic method will evaluate pain levels. Hospital length of stay will be measured from date of admission to date of discharge.

The study drug, Ofiramev® (acetaminophen) injection is a non-salicylate antipyretic and non-opioid analgesic agent. The precise mechanism of the analgesic and antipyretic properties of acetaminophen is not established but is thought to primarily involve central actions. The study drug is a clear, colorless formulation of acetaminophen intended for intravenous infusion and is packaged in glass vials containing 100 mL of 1000 mg acetaminophen (10 mg/mL). The investigational pharmacy will transfer the study drug to a 100 mL bag. The placebo solution will consist of 100 mL normal saline in an identical 100 mL bag with identical labeling. Prior to the induction of anesthesia subjects will receive a single dose of Ofiramev® or placebo by IV infusion over 15 minutes. Following the first dose, each subsequent dose will be given every 6 hours for a total of 4 doses. Regardless of treatment arm, study drug and placebo will be dispensed in the same manner.

Investigational drugs are stored in the investigational drug service storeroom and/or pharmacy satellite depending on the nature of the drug study. All study drug inventory is labeled with IRB identification and stored separately from other commercial drug products under appropriate security and stability conditions. OFIRMEV should be stored at 20°C to 25°C (68°F to 77°F) and should be used within 6 hours after opening.

An accurate and current accounting of the dispensing and return of study drug for each subject will be maintained on an ongoing basis by a member of the study site staff. The number of study drug dispensed and returned by the subject will be recorded on the Investigational Drug Accountability Record. The study monitor will verify these documents throughout the course of the study.

Patients can voluntarily withdraw from the trial for any reason at any time. Subjects will be withdrawn from the study in the event of unplanned conversion to open thoracic surgery or administration of neuraxial opioids. If a subject is withdrawn from treatment due to an adverse event, the subject will be followed and treated by the Investigator until the abnormal parameter or symptom has resolved or stabilized. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03051932
Study type Interventional
Source The University of Texas Medical Branch, Galveston
Contact
Status Withdrawn
Phase N/A
Start date June 1, 2018
Completion date June 1, 2019

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04585620 - Botulinum Toxin A as Treatment for Chronic Postsurgical Pain Following Lung Cancer Surgery Phase 1/Phase 2
Recruiting NCT03538340 - Intraoperative Cryoanalgesia for Extended Pain Management Following Thoracotomy N/A
Completed NCT04990700 - Effect of Partial Rib Resection On the Control of Post-thoracotomy Pain N/A
Recruiting NCT05379816 - Persistent Pain Induced by Uniportal Video-assisted Thoracic Surgery N/A
Completed NCT05962736 - The Effect of Mirror Therapy After Thoracotomy N/A
Completed NCT04531553 - Erector Spinae Plane Block for Post-thoracotomy Pain Control N/A
Completed NCT06398834 - Esketamine and Butorphanol for Post-Lobectomy Pain Phase 4
Not yet recruiting NCT05409144 - Impact of Thoracic Epidural Versus Serratus Anterior Plane Block Versus Erector Spinae Plane Block on Incidence of PTPS N/A
Recruiting NCT04415242 - IMPACT OF OPERATIVE POSITIONING ON THE DEVELOPMENT OF SHOULDER PAIN AFTER PULMONARY LOBECTOMY BY VATS N/A
Recruiting NCT05791539 - Comparison Between Retrolaminar Block Combined With Erector Spinae Plane Block, and Erector Spinae Plane Block Alone for Post-thoracotomy Pain N/A
Terminated NCT04258436 - Serratus Anterior Plane Block for Management of Post Thoracotomy Pain N/A
Completed NCT02619513 - Effects of Dexmedetomidine Used in Continuous Thoracic Paravertebral Blocks Phase 4
Completed NCT04189120 - The Effect of Ultrasound Guided Superficial, Deep Serratus Plane Blocks and Thoracic Epidural in Thoracotomy N/A